Lactic acidemia and bradyarrhythmia in a child sedated with propofol.
OBJECTIVE
To describe a severe adverse reaction in a child who received an infusion of propofol for sedation in the intensive care unit (ICU). To describe the management and further investigation of this patient and review similar published reports.


METHODS
Case report and literature review.


METHODS
Community hospital ICU and tertiary pediatric ICU.


METHODS
Infant with upper respiratory obstruction secondary to an esophageal foreign body who required tracheal intubation and mechanical ventilation.


METHODS
Conventional cardiovascular and respiratory support. Continuous veno-venous hemofiltration (CVVH) and plasmapheresis.


RESULTS
The patient received a propofol infusion at a mean rate of 10 mg/kg/hr for 50.5 hrs. He developed lipemia and green urine and subsequently, a progressive severe lactic acidemia and bradyarrhythmias unresponsive to conventional treatment. These abnormalities resolved with CVVH. He was encephalopathic and developed liver and muscle necrosis histologically compatible with a toxic insult. Examination of homogenized muscle tissue demonstrated a reduction in cytochrome C oxidase activity. There was no evidence of systemic infection or underlying metabolic disease. He eventually recovered completely.


CONCLUSIONS
Propofol has been associated with severe adverse reactions in children receiving intensive care. The biochemical and histologic abnormalities described in this patient may guide further investigation. We advise against prolonged use of propofol for sedation in children.
Cray
S H
SH
Department of Critical Care Medicine, The Hospital for Sick Children, Toronto, ON, Canada.
Robinson
B H
BH
Cox
P N
PN
D000140:Acidosis, Lactic / Q000139:chemically induced* / Q000175:diagnosis / Q000378:metabolism; D001919:Bradycardia / Q000139:chemically induced* / Q000175:diagnosis / Q000378:metabolism; D016292:Procedural Sedation / Q000009:adverse effects*; D005234:Fatty Liver / Q000139:chemically induced / Q000473:pathology; D006801:Humans; D006949:Hyperlipidemias / Q000139:chemically induced; D006993:Hypnotics and Sedatives / Q000009:adverse effects*; D007223:Infant; D007262:Infusions, Intravenous; D008297:Male; D009135:Muscular Diseases / Q000139:chemically induced / Q000473:pathology; D009336:Necrosis; D009846:Oliguria / Q000139:chemically induced; D015742:Propofol / Q000009:adverse effects*; D012121:Respiration, Artificial
D006993:Hypnotics and Sedatives; D015742:Propofol